论文部分内容阅读
目的:探讨沙美特罗/氟替卡松(50/500)吸入对缓解期的慢性阻塞性肺疾病(COPD)患者的治疗效果。方法:将2007年1月至2008年12月收治于我院的216例处于缓解期的COPD患者随机分为3组,对照组(72例)、低剂量治疗组(72例)和高剂量治疗组(72例),对照组患者行常规治疗,低剂量治疗组患者在常规治疗基础上给予美特罗/氟替卡松(50μg/250μg)吸入,高剂量治疗组患者在常规治疗基础上给予美特罗/氟替卡松(50μg/500μg)吸入。分析比较3组患者在治疗前后的临床疗效、肺功能变化以及血气方面的区别。结果:高剂量治疗组在临床疗效、肺功能变化以及血气分析等方面均优于低剂量治疗组,低剂量治疗组优于对照组。结论:吸入沙美特罗/氟替卡松(50/500)能改善COPD患者的临床症状,能提高患者的肺功能和生存质量,值得推广应用。
Objective: To investigate the effect of salmeterol / fluticasone (50/500) inhalation on patients with chronic obstructive pulmonary disease (COPD) during remission. Methods: A total of 216 remission COPD patients admitted to our hospital from January 2007 to December 2008 were randomly divided into three groups: control group (72 cases), low dose treatment group (72 cases) and high dose treatment (72 cases). Patients in the control group were treated routinely. Patients in the low-dose treatment group were given metoprolol / fluticasone (50μg / 250μg) inhalation on the basis of conventional treatment. Patients in the high-dose treatment group were given metoterol / Fluticasone (50 [mu] g / 500 [mu] g). The clinical efficacy, changes in lung function and blood gas were compared between the three groups before and after treatment. Results: The high-dose treatment group was superior to the low-dose treatment group in terms of clinical efficacy, changes in lung function and blood gas analysis. The low-dose treatment group was superior to the control group. Conclusion: Salmeterol / fluticasone (50/500) inhalation can improve the clinical symptoms of patients with COPD, can improve lung function and quality of life of patients, it is worth popularizing and applying.